Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-06 pm EST
55.21 USD   +0.80%
05:42pInsider Sell: Apellis Pharmaceuticals
MT
01/25Insider Sell: Apellis Pharmaceuticals
MT
01/09Transcript : Apellis Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 09:00 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Apellis Says FDA Accepts Amended New Drug Application for Eye Disease Drug Candidate; Shares Higher

11/18/2022 | 01:13pm EST


ę MT Newswires 2022
All news about APELLIS PHARMACEUTICALS, INC.
05:42pInsider Sell: Apellis Pharmaceuticals
MT
01/25Insider Sell: Apellis Pharmaceuticals
MT
01/09Transcript : Apellis Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morga..
CI
01/09Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635
AQ
01/06Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
GL
01/06Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
AQ
01/05Apellis Pharmaceuticals, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
01/05Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
GL
01/05Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
GL
01/05Apellis Appoints Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
CI
More news
Analyst Recommendations on APELLIS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 77,4 M - -
Net income 2022 -660 M - -
Net cash 2022 391 M - -
P/E ratio 2022 -8,80x
Yield 2022 -
Capitalization 6 099 M 6 099 M -
EV / Sales 2022 73,7x
EV / Sales 2023 29,3x
Nbr of Employees 476
Free-Float 84,6%
Chart APELLIS PHARMACEUTICALS, INC.
Duration : Period :
Apellis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APELLIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 55,21 $
Average target price 74,69 $
Spread / Average Target 35,3%
EPS Revisions
Managers and Directors
Cedric Francois President, Chief Executive Officer & Director
Timothy Eugene Sullivan Chief Financial Officer & Treasurer
Lok Chung Chan Chairman
Pascal Deschatelets Chief Scientific Officer
Nur Nicholson Chief Technical Operations Officer
Sector and Competitors